Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Hawthorne TR"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Alvarado D; Celldex Therapeutics, Hampton, New Jersey, USA., Maurer M; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universtätsmedizin Berlin, Germany.; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany., Gedrich R; Celldex Therapeutics, Hampton, New Jersey, USA., Seibel SB; Celldex Therapeutics, Hampton, New Jersey, USA., Murphy MB; Celldex Therapeutics, Hampton, New Jersey, USA., Crew L; Celldex Therapeutics, Hampton, New Jersey, USA., Goldstein J; Celldex Therapeutics, Hampton, New Jersey, USA., Crocker A; Celldex Therapeutics, Hampton, New Jersey, USA., Vitale LA; Celldex Therapeutics, Hampton, New Jersey, USA., Morani PA; Celldex Therapeutics, Hampton, New Jersey, USA., Thomas LJ; Celldex Therapeutics, Hampton, New Jersey, USA., Hawthorne TR; Celldex Therapeutics, Hampton, New Jersey, USA., Keler T; Celldex Therapeutics, Hampton, New Jersey, USA., Young D; Celldex Therapeutics, Hampton, New Jersey, USA., Crowley E; Celldex Therapeutics, Hampton, New Jersey, USA., Kankam M; Altasciences Clinical Kansas, Overland Park, Kansas, USA., Heath-Chiozzi M; Celldex Therapeutics, Hampton, New Jersey, USA.
Publikováno v:
Allergy [Allergy] 2022 Aug; Vol. 77 (8), pp. 2393-2403. Date of Electronic Publication: 2022 Mar 03.
Autor:
Sanborn RE; Providence Cancer Institute, Earle A. Chiles Research Institute, Portland, Oregon, USA Rachel.sanborn@providence.org., Pishvaian MJ; Department of Oncology, Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA., Callahan MK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Weise A; Karmanos Cancer Institute, Detroit, Michigan, USA., Sikic BI; Clinical and Translational Research Unit, Stanford Cancer Institute, Stanford, California, USA., Rahma O; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA., Cho DC; Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York, USA., Rizvi NA; Division of Hematology/Oncology, Columbia University Medical Center, New York, New York, USA., Sznol M; Smilow Cancer Hospital, New Haven, Connecticut, USA., Lutzky J; Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, USA., Bauman JE; University of Arizona Cancer Center, Tuscon, Arizona, USA., Bitting RL; Wake Forest Baptist Health, Winston-Salem, North Carolina, USA., Starodub A; Parkview Research Center, Fort Wayne, Indiana, USA., Jimeno A; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Reardon DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Kaley T; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Iwamoto F; Department of Neurology, Columbia Presbyterian Medical Center, New York, New York, USA., Baehring JM; Department of Neurosurgery, Yale New Haven Health Smilow Cancer Hospital, New Haven, Connecticut, USA., Subramaniam DS; Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA., Aragon-Ching JB; Inova Schar Cancer Institute, Fairfax, Virginia, USA., Hawthorne TR; Celldex Therapeutics Inc New Haven, New Haven, Connecticut, USA., Rawls T; Celldex Therapeutics Inc, Hampton, New Jersey, USA., Yellin M; Celldex Therapeutics Inc, Hampton, New Jersey, USA., Keler T; R & D, Celldex Therapeutics Inc, Hampton, New Jersey, USA.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Aug; Vol. 10 (8).
Autor:
Ansell SM; Division of Hematology, Mayo Clinic, Rochester, MN., Flinn I; Center for Blood Cancer, Sarah Cannon Research Institute, Nashville, TN., Taylor MH; Franz Cancer Center, Providence Portland Medical Center, Portland, OR., Sikic BI; Clinical and Translational Research Unit, Stanford Cancer Institute, Stanford, CA., Brody J; Division of Hematology and Oncology, Mount Sinai Medical Center, New York, NY., Nemunaitis J; Division of Hematology, University of Toledo College of Medicine and Life Sciences, Toledo, OH; and., Feldman A; Division of Hematology, Mayo Clinic, Rochester, MN., Hawthorne TR; Celldex Therapeutics, Inc., Hampton, NJ., Rawls T; Celldex Therapeutics, Inc., Hampton, NJ., Keler T; Celldex Therapeutics, Inc., Hampton, NJ., Yellin MJ; Celldex Therapeutics, Inc., Hampton, NJ.
Publikováno v:
Blood advances [Blood Adv] 2020 May 12; Vol. 4 (9), pp. 1917-1926.
Autor:
Ott PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Pavlick AC; Department of Medical Oncology, New York University School of Medicine, New York, New York., Johnson DB; Department of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee., Hart LL; Florida Cancer Specialists and Research Institute, Fort Myers, Florida., Infante JR; Tennessee Oncology, PLLC, Nashville, Tennessee., Luke JJ; Department of Hematology/Oncology, University of Chicago Medical Center, Chicago, Illinois., Lutzky J; Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida., Rothschild NE; Florida Cancer Specialists, West Palm Beach, Florida., Spitler LE; St. Mary's Medical Center, San Francisco, California., Cowey CL; Northern California Melanoma Center, Baylor University Medical Center, Dallas, Texas., Alizadeh AR; Northside Hospital Cancer Institute, Decatur, Georgia., Salama AK; Department of Medical Oncology, Duke University, Durham, North Carolina., He Y; Celldex Therapeutics, Inc, Hampton, New Jersey., Hawthorne TR; Celldex Therapeutics, Inc, Hampton, New Jersey., Bagley RG; Celldex Therapeutics, Inc, Hampton, New Jersey., Zhang J; Celldex Therapeutics, Inc, Hampton, New Jersey., Turner CD; Celldex Therapeutics, Inc, Hampton, New Jersey., Hamid O; The Angeles Clinic and Research Institute, Los Angeles, California.
Publikováno v:
Cancer [Cancer] 2019 Apr 01; Vol. 125 (7), pp. 1113-1123. Date of Electronic Publication: 2019 Jan 28.
Autor:
Burris HA; Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ., Infante JR; Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ., Ansell SM; Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ., Nemunaitis JJ; Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ., Weiss GR; Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ., Villalobos VM; Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ., Sikic BI; Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ., Taylor MH; Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ., Northfelt DW; Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ., Carson WE 3rd; Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ., Hawthorne TR; Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ., Davis TA; Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ., Yellin MJ; Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ., Keler T; Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ., Bullock T; Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2017 Jun 20; Vol. 35 (18), pp. 2028-2036. Date of Electronic Publication: 2017 May 02.
Autor:
Ara G; CuraGen Corporation, Branford, Connecticut, USA., Watkins BA, Zhong H, Hawthorne TR, Karkaria CE, Sonis ST, Larochelle WJ
Publikováno v:
International journal of radiation biology [Int J Radiat Biol] 2008 May; Vol. 84 (5), pp. 401-12.
Autor:
Hawthorne TR; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville 32610, USA., Austin JK Jr
Publikováno v:
Cancer letters [Cancer Lett] 1996 Jan 19; Vol. 99 (1), pp. 99-107.